Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Next-Generation Antibody Therapeutics Market from 2024 to 2025?
In recent times, there has been a quick expansion in the size of the next-generation antibody therapeutics market. Analogous to this trend, it is projected to enlarge from $6.82 billion in 2024 to reach $7.63 billion in 2025, representing a compound annual growth rate (CAGR) of 11.8%. This growth during the historical period can be linked to the success of monoclonal antibody, the increasing frequency of chronic ailments, authorisation of antibody-drug conjugates, along with the advancement of immunotherapy, gene therapy and antibodies.
What Is the Projected Market Size of the Next-Generation Antibody Therapeutics Market?
The market size of the next-generation antibody therapeutics is projected to witness a swift expansion in the coming years. It is predicted to escalate to $11.52 billion by the year 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth throughout the predicted period can be credited to several factors such as the development of biosimilars, bispecific antibodies, and nanobody, patient-centric methodologies, immunomodulatory antibodies, and growing applications in autoimmune diseases along with constant manufacturing. Key emerging trends throughout the forecast timeline will be the progress in antibody engineering, implementation of digital technologies in antibody designs, industry partnerships, breakthroughs in drug delivery systems, and usage of real-world evidence in antibody evolution.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp
Who are the Major Competitors in the Next-Generation Antibody Therapeutics Market Outlook?
Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.
What Is Fueling Growth in the Next-Generation Antibody Therapeutics Market?
The rising prevalence of chronic diseases is anticipated to spur the next-generation antibody therapeutics market’s expansion. Chronic diseases, which typically last for a year or longer, often necessitate continued medical care and can limit daily activities. These advanced antibody therapeutics provide targeted care for individuals suffering from chronic diseases, potentially improving their health outcomes. For example, by January 2023, the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, predicted that the number of people aged 50 and above with at least one chronic illness will increase by 99.5% by 2050, to a staggering 142.66 million. Consequently, this rise in chronic diseases is fueling the growth of the next-generation antibody therapeutics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp
Which Next-Generation Antibody Therapeutics Market Segments Are Growing the Fastest?
The next-generation antibody therapeutics market covered in this report is segmented –
1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies
2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies
3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types
5) By Other Types: Nanobodies, Engineered Antibodies
Which Industry Trends Are Shaping the Future of the Next-Generation Antibody Therapeutics Market?
The trend of technological advancements is becoming increasingly prevalent within the next-generation antibody therapeutics market. Major market players are emphasizing on the development of advanced technologies such as proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology to amplify protein identification and profiling, thereby enabling more precise and targeted treatments. The objective of these progressions is to enhance therapeutic profiles, reduce expenditures, and effectively tackle complex diseases. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a technology that arranges protein molecules into organized assemblies for improved analysis and measurement. This improves the sensitivity and precision of protein detection, which is valuable in research and diagnostic scenarios. For example, in January 2024, Infinity Bio, Inc., a biotechnology firm based in the US, introduced a next-generation antibody profiling platform that employs MIPSA technology for extensive, cost-effective analysis of immune response, with the goal of improving disease knowledge and tailoring treatment approaches.
Access The Full Report Here:
Which Countries Are Leading the Next-Generation Antibody Therapeutics Market?
North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12678
This Report Delivers Insight On:
1. How big is the next-generation antibody therapeutics market, and how is it changing globally?
2. Who are the major companies in the next-generation antibody therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the next-generation antibody therapeutics market right now?
4. Which products or customer segments are growing the most in the next-generation antibody therapeutics market?
5. What factors are helping or slowing down the growth of the next-generation antibody therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
